152 related articles for article (PubMed ID: 3113225)
1. Usefulness of intravenous thrombolytic therapy with pro-urokinase in acute myocardial infarction.
Bode C; Schuler G; Schwarz F; Zimmermann R; Horn A; Kuebler W
Am J Cardiol; 1987 Aug; 60(4):371. PubMed ID: 3113225
[No Abstract] [Full Text] [Related]
2. Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
Gulba DC; Bode C; Sen S; Topp J; Fischer K; Wolf H; Hecker H
Cathet Cardiovasc Diagn; 1992 Jul; 26(3):177-84. PubMed ID: 1617708
[TBL] [Abstract][Full Text] [Related]
3. [A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study].
Kambara H; Kawai C; Kajiwara N; Kammatsuse K; Nitani H; Sasayama S; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Kokyu To Junkan; 1989 Jul; 37(7):749-56. PubMed ID: 2678331
[TBL] [Abstract][Full Text] [Related]
4. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
[TBL] [Abstract][Full Text] [Related]
5. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents.
Collen D; Stump DC; Van de Werf F
Am Heart J; 1986 Nov; 112(5):1083-4. PubMed ID: 3096127
[No Abstract] [Full Text] [Related]
6. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
[TBL] [Abstract][Full Text] [Related]
7. [Thrombolytic therapy in acute myocardial infarct].
Bode C; Baumann H; von Hodenberg E; Kübler W
Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
[No Abstract] [Full Text] [Related]
8. Clot-selective coronary thrombolysis with pro-urokinase.
Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
[TBL] [Abstract][Full Text] [Related]
9. [The choice of appropriate thrombolytic agents as therapy in acute heart infarct].
Görge G; Meyer J
Med Klin (Munich); 1992 Feb; 87(2):70-80, 108. PubMed ID: 1542286
[No Abstract] [Full Text] [Related]
10. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Czyrski J
Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
[TBL] [Abstract][Full Text] [Related]
11. Pro-UK: another entry in the thrombolytic arena.
Goldsmith MF
JAMA; 1985 Mar 22-29; 253(12):1694-5. PubMed ID: 3919191
[No Abstract] [Full Text] [Related]
12. Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Bode C; Nordt TK; Runge MS
Ann Hematol; 1994 Oct; 69(4):S35-40. PubMed ID: 7948298
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic therapy for acute myocardial infarction--round 2.
Lancet; 1988 Mar; 1(8585):565-7. PubMed ID: 2894496
[No Abstract] [Full Text] [Related]
14. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
15. The effects of thrombolytic therapy on the high-resolution electrocardiogram after myocardial infarction.
Mäkijärvi M; Heikkilä J; Montonen J; Leiniö M; Siltanen P; Katila T
Eur Heart J; 1992 Aug; 13(8):1046-52. PubMed ID: 1505553
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325
[TBL] [Abstract][Full Text] [Related]
17. Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
Park SJ
Am J Cardiol; 1998 Sep; 82(6):811-3, A10. PubMed ID: 9761098
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between raised serum Lp(a) concentration and unsuccessful thrombolysis after acute myocardial infarction.
Armstrong VW; Neubauer C; Schütz E; Tebbe U
Lancet; 1990 Oct; 336(8722):1077. PubMed ID: 1977059
[No Abstract] [Full Text] [Related]
19. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.
Semba CP; Bakal CW; Calis KA; Grubbs GE; Hunter DW; Matalon TA; Murphy TP; Stump DC; Thomas S; Warner DL
J Vasc Interv Radiol; 2000 Mar; 11(3):279-87. PubMed ID: 10735420
[No Abstract] [Full Text] [Related]
20. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
